Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: Co-prescribed/Concomitant therapies
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Co-prescribed/Concomitant therapies

1 evidence topic · 1 source

French consensus protocol: accompanying immunosuppression

“steroids, rATG, high dose IVIg, rituximab, tacrolimus and mycophenolic acid.” (opens the source at this quote in a new tab)